Author:
Hofeichner Janessa,Gahr Bernd Martin,Huber Magdalena,Boos Alena,Rottbauer Wolfgang,Just Steffen
Abstract
AbstractNexilin (NEXN) plays a crucial role in stabilizing the sarcomeric Z-disk of striated muscle fibers and, when mutated, leads to dilated cardiomyopathy in humans. Due to its early neonatal lethality in mice, the detailed impact of the constitutive homozygous NEXN knockout on heart and skeletal muscle morphology and function is insufficiently investigated. Here, we characterized a constitutive homozygous CRISPR/Cas9-mediated nexn knockout zebrafish model. We found that Nexn deficient embryos developed significantly reduced cardiac contractility and under stressed conditions also impaired skeletal muscle organization whereas skeletal muscle function seemed not to be affected. Remarkably, in contrast to nexn morphants, CRISPR/Cas9 nexn−/− knockout embryos showed a milder phenotype without the development of a pronounced pericardial edema or blood congestion. nexn-specific expression analysis as well as whole transcriptome profiling suggest some degree of compensatory mechanisms. Transcripts of numerous essential sarcomeric proteins were massively induced and may mediate a sarcomere stabilizing function in nexn−/− knockout embryos. Our findings demonstrate the successful generation and characterization of a constitutive homozygous nexn knockout line enabling the detailed investigation of the role of nexn on heart and skeletal muscle development and function as well as to assess putative compensatory mechanisms induced by the loss of Nexn.
Funder
Deutsche Forschungsgemeinschaft
German Federal Ministry of Education and Research
Universitätsklinikum Ulm
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. World Health Organization. Cardiovascular diseases. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (2023).
2. Ciarambino, T., Menna, G., Sansone, G. & Giordano, M. Cardiomyopathies: An overview. Int. J. Mol. Sci. 22, 7722 (2021).
3. Richardson, P. et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93, 841–842 (1996).
4. Japp, A. G., Gulati, A., Cook, S. A., Cowie, M. R. & Prasad, S. K. The diagnosis and evaluation of dilated cardiomyopathy. J. Am. Coll. Cardiol. 67, 2996–3010 (2016).
5. McNally, E. M., Golbus, J. R. & Puckelwartz, M. J. Genetic mutations and mechanisms in dilated cardiomyopathy. J. Clin. Investig. 123, 19–26 (2013).